Peritoneal (PD) and hemodialysis (HD) represent the leading renal replacement therapies in advanced chronic kidney disease (CKD). Although absolutely necessary to ensure patient survival, these treatments are responsible for considerable biological alterations primarily due to the un-physiological contact of blood and tissues with bioincompatible devices or plastificants. Although extensively described, this complex dialysis-related deregulated bio-molecular machinery is still not completely known. Therefore, to select a set of genes deregulated in patients on dialysis treatment and to assess the possible differences between dialysis modalities, we measured the expression level of 132 genes involved in proteoglycans (PGs) biosynthesis/metabolism by microarray in peripheral blood mononuclear cells (PBMCs), biological elements involved in the inflammatory/immune response, from 5 healthy subjects (HS), 9 CKD, 10 PD, and 17 HD patients. We focused on PGs biosynthesis/metabolism pathways because of their involvement in the onset and development of several CKD-related clinical complications. Statistical analysis/bioinformatics identified 70 genes discriminating HD/PD patients from HS/CKD subjects (P < 0.009, FDR < 5%). Twenty-five genes were up-regulated (e.g. HPSE, VCAN, and VEGFA) and 45 down-regulated (e.g. IDS and HEXA) in PD/HD compared to HS/CKD. Gene expression and plasma activity of Heparanase (HPSE), one of the top selected up-regulated genes in PD/HD, validated microarray results. In addition, for the second part of the study, HPSE plasmatic activities were first assessed in an independent testing-group (7 HS, 10 CKD, 17 PD, and 11 HD), and then correlated with high-sensitive C reactive protein (HS-CRP) measurements. HPSE activity was higher in PD and HD versus CKD/HS and it correlated with HS-CRP levels (R2 = 0.37, P = 0.007). Lipopolysaccharide (LPS)-stimulated PBMCs showed a significant up-regulation of HPSE mRNA level (P = 0.04). Our results revealed that dialysis treatments induce change in the transcriptomic pattern of biosynthetic proteoglycans in PBMCs with an up-regulation of HPSE. Our selected genes could be useful in the future as potential biomarkers and new therapeutic targets.
BloembergenWEPortFKMaugerEAWolfeRA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol1995; 6: 184–91.
2.
HaddyFJMeyerTW. Uremia. N Engl J Med2007; 357: 1316–25.
3.
CoreshJAstorBCGreeneTEknoyanGLeveyAS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis2003; 41: 1–12.
4.
HamerRAEl NahasAM. The burden of chronic kidney disease. BMJ2006; 332: 563–4.
5.
GrassmannAGiobergeSMoellerSBrownG. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant2005; 20: 2587–93.
6.
FoleyRNParfreyPS. Cardiovascular disease and mortality in ESRD. J Nephrol1998; 11: 239–45.
7.
CibulkaRRacekJ. Metabolic disorders in patients with chronic kidney failure. Physiol Res2007; 56: 697–705.
8.
RitzE. Metabolic syndrome and kidney disease. Blood Purif2008; 26: 59–62.
9.
CharraB. Fluid balance, dry weight, and blood pressure in dialysis. Hemodial Int2007; 11: 21–31.
10.
DepnerTA. Uremic toxicity: urea and beyond. Semin Dial2001; 14: 246–51.
11.
GranataSZazaGSimoneSVillaniGLatorreDPontrelliPCarellaMSchenaFPGrandalianoGPertosaG. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics2009; 10: 388–388.
12.
GesualdoLPertosaGGrandalianoGSchenaFP. Cytokines and bioincompatibility. Nephrol Dial Transplant1998; 13: 1622–6.
13.
ZazaGPontrelliPPertosaGGranataSRossiniMPorrecaSStaalFJGesualdoLGrandalianoGSchenaFP. Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrol Dial Transplant2008; 23: 1673–81.
14.
PesceFPathanSSchenaFP. From -omics to personalized medicine in nephrology: integration is the key. Nephrol Dial Transplant2013; 28: 24–8.
15.
ZazaGGranataSSallustioFGrandalianoGSchenaFP. Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin Exp Immunol2010; 159: 268–80.
16.
Vivekanandan-GiriASlocumJLBullerCLBasrurVJuWPop-BusuiRLubmanDMKretzlerMPennathurS. Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics2011; 2011: 214715–214715.
17.
SalmonAHFergusonJKBurfordJLGevorgyanHNakanoDHarperSJBatesDOPeti-PeterdiJ. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol2012; 23: 1339–50.
18.
CouchmanJRPatakiCA. An introduction to proteoglycans and their localization. J Histochem Cytochem2012; 60: 885–97.
19.
TaylorKRGalloRL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J2006; 20: 9–22.
20.
Cohen-MazorMSelaSMazorRIlanNVlodavskyIRopsALvan der VlagJCohenHIKristalB. Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients?Am J Physiol Heart Circ Physiol2008; 294: H651–8.
21.
XuXQuirosRMMaxhimerJBJiangPMarcinekRAinKBPlattJLShenJGattusoPPrinzRA. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res2003; 9: 5968–79.
22.
The Gene Ontology consortium. The Gene Ontology project in 2008. Nucleic Acid Res2008; 36: D440–4.
23.
GolubTRSlonimDKTamayoPHuardCGaasenbeekMMesirovJPCollerHLohMLDowningJRCaligiuriMABloomfieldCDLanderES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science1999; 286: 531–7.
FreyHSchroederNManon-JensenTIozzoRVSchaeferL. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J2013; 280: 2165–79.
26.
StrandMEHerumKMRanaZASkrbicBAskevoldETDahlCPVistnesMHasicAKvaløyHSjaastadICarlsonCRTønnessenTGullestadLChristensenGLundeIG. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J2013; 280: 2228–47.
27.
CollinsAJFoleyRNGilbertsonDTChenSC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol2009; 4: S5–11.
28.
KendrickJTeitelbaumI. Strategies for improving long-term survival in peritoneal dialysis patients. Clin J Am Soc Nephrol2010; 5: 1123–31.
29.
KaysenGA. The microinflammatory state in uremia. Causes and potential consequences. J Am Soc Nephrol2001; 12: 1549–57.
30.
OsterudBBjorklidE. Role of monocytes in atherogenesis. Physiol Rev2003; 83: 1069–112..
31.
HanssonGK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med2005; 352: 1685–95.
32.
YeunJYLevineRAMantadilokVKaysenGA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis2000; 35: 469–76.
33.
ZimmermannJHerrlingerSPruyAMetzgerTWannerC. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int1999; 55: 648–58.
34.
AkahoshiTKobayashiNHosakaSSekiyamaNWadaCKondoH. In vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant1995; 10: 2244–9.
35.
HerbelinAUreñaPNguyenATZingraffJDescamps-LatschaB. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int1991; 39: 954–60.
36.
LonnemannGvan der MeerJWCannonJGDinarelloCAKochKMGranollerasCDeschodtGShaldonS. Induction of tumor necrosis factor during extracorporeal blood purification. N Engl J Med1987; 317: 963–4.
37.
NakanishiIMoutabarrikAOkadaNKitamuraEHayashiASyoujiTNamikiMIshibashiMZaidDTsubakiharaY. Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant1994; 9: 1435–42.
38.
KimSOhJKimSChungWAhnCKimSGOhKH. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant2009; 24: 2899–908.
39.
HoffCM. In vitro biocompatibility performance of Physioneal. Kidney Int Suppl2003; 88: S57–74.
40.
PajekJKvederRBrenAGucekABucarMSkoberneAWaniewskiJLindholmB. Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant2009; 24: 1617–25.
41.
GlikADouvdevaniA. T lymphocytes: the “cellular” arm of acquired immunity in the peritoneum. Perit Dial Int2006; 26: 438–48.
42.
WalterRMischakHHallerH. Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients. Nephrol Dial Transplant2002; 17: 24–9.
43.
BartoldPMHarkinDGBignoldLP. Proteoglycans synthesized by human polymorphonuclear leucocytes in vitro. Immunol Cell Biol1989; 67: 9–17.
44.
WilflingsederJPercoPKainzAKorbélyRMayerBOberbauerR. Biocompatibility of haemodialysis membranes determined by gene expression of human leucocytes: a crossover study. Eur J Clin Invest2008; 38: 918–24.
45.
FriedrichBAlexanderDJanessaAHäringHULangFRislerT. Acute effects of hemodialysis on cytokine transcription profiles: evidence for C-reactive protein-dependency of mediator induction. Kidney Int2006; 70: 2124–2130..
46.
ZazaGGranataSRascioFPontrelliPDell'OglioMPCoxSNPertosaGGrandalianoGLupoA. A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients. BMC Med Genomics2013; 6: 17.–17..
47.
SchaeferLSchaeferRM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res2010; 339: 237–46.
48.
WuYJLa PierreDPWuJYeeAJYangBB. The interaction of versican with its binding partners. Cell Res2005; 15: 483–94.
49.
WightTN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol2002; 14: 617–23.
50.
NorianJMMalikMParkerCYJosephDLeppertPCSegarsJHCatherinoWH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci2009; 16: 1153–64.
51.
LemireJMChanCKBresslerSMillerJLeBaronRGWightTN. Interleukin-1beta selectively decreases the synthesis of versican by arterial smooth muscle cells. J Cell Biochem2007; 101: 753–66.
52.
TammelaTEnholmBAlitaloKPaavonenK. The biology of vascular endothelial growth factors. Cardiovasc Res2005; 65: 550–63.
53.
ChungASFerraraN. Developmental and pathological angiogenesis. Ann Rev Cell Dev Biol2011; 27: 563–84.
54.
Osada-OkaMIkedaTImaokaSAkibaSSatoT. VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells. J Atheroscler Thromb2008; 15: 26–33.
55.
DvorakHFBrownLFDetmarMDvorakAM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol1995; 146: 1029–39.
56.
KeckPJHauserSDKriviGSanzoKWarrenTFederJConnollyDT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science1989; 246: 1309–12.
57.
ScholzeABladbjergEMSidelmannJJDiederichsenACMickleyHNyboMArgravesWSMarckmannPRasmussenLM. Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovasc Diabetol2013; 12: 6–6.
58.
MasolaVOnistoMZazaGLupoAGambaroG. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med2012; 10: 213–213.
59.
MasolaVGambaroGTibaldiEBrunatiAMGastaldelloAD'AngeloAOnistoMLupoA. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem2012; 287: 1478–88.
60.
MasolaVMaranCTassoneEZinARosolenAOnistoM. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer2009; 28: 304–304.
61.
DempseyLABrunnGJPlattJL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci2000; 25: 349–51..
62.
BarashUCohen-KaplanVDowekISandersonRDIlanNVlodavskyI. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J2010; 277: 3890–903.
63.
IlanNElkinMVlodavskyI. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol2006; 38: 2018–39.
64.
RaoGDingHGHuangWLeDMaxhimerJBOosterhofAvan KuppeveltTLumHLewisEJReddyVPrinzRAXuX. Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia2011; 54: 1527–38.
65.
BakerABGibsonWJKolachalamaVBGolombMIndolfiLSpruellCZchariaEVlodavskyIEdelmanER. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol2012; 59: 1551–60.
66.
RopsALvan den HovenMJVeldmanBASaleminkSVervoortGElvingLDAtenJWetzelsJFvan der VlagJBerdenJH. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrol Dial Transplant2012; 27: 2853–61.
67.
Ben ArushMWShafatIBen BarakAShalomRBVlodavskyIIlanN. Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study. Pediatr Hematol Oncol2009; 26: 157–64.
68.
NgkeloAMejaKYeadonMAdcockIKirkhamPA. LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Giα dependent PI-3kinase signalling. J Inflamm (Lond)2012; 9: 1–1.
69.
AmoreACoppoR. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant2002; 17: 16–24.
70.
PertosaGGrandalianoGGesualdoLSchenaFP. Clinical relevance of cytokine production in hemodialysis. Kidney Int Suppl2000; 76: S104–11.
BaccheschiSSereniLDe NittiCBarbucciRTettaC. Blood tubing and cytokine production: effect of sterilization. Ren Fail2001; 23: 411–8.
73.
SzetoCCKwanBCChowKMLaiKBChungKYLeungCBLiPK. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol2008; 3: 431–6.
74.
GuthHJGruskaSKraatzG. The measurement of cytokine production capacity during dialysis–a new dynamic method for the evaluation of biocompatibility?Int J Artif Organ2000; 23: 675–9.
75.
FischerWHJagelsMAHugliTE. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol1999; 162: 453–9.
